Latest Capital Raise News

Cosmos Exploration’s optioned entity, EAU Lithium, has agreed to acquire a fully constructed pilot plant from Vulcan Energy Resources to advance lithium extraction testing in Bolivia. This move strengthens Cosmos’ strategic foothold in one of the world’s most promising lithium regions.

Control Bionics Limited has announced a $2.06 million non-renounceable rights issue to fund the commercial expansion of its NeuroStrip device and bolster NeuroNode operations. The capital raise is underwritten to approximately $1.15 million by major shareholders and strategic partners.

Zoono Group Limited reported a 19.1% revenue increase to NZ$1.25 million for FY2025, alongside a significantly reduced net loss. The company is pivoting towards B2B markets, focusing on antimicrobial and shelf-life extension technologies, supported by a recent AUD 1.78 million capital raise.

Tetratherix Limited reports its first financial results as a listed company, revealing a $9.4 million statutory loss driven by R&D and listing costs, alongside a robust $29.3 million cash position post-IPO. The company highlights key operational milestones and outlines strategic plans to accelerate commercialisation across its innovative biomaterial platform.

DXN Limited reported a robust 49% revenue increase to $16 million in FY25, driven by modular data centre projects and the launch of a new Data Centre as a Service division. Key contracts with blue-chip clients and a strong project pipeline position the company for further expansion in the Asia-Pacific market.

Lynas Rare Earths has launched a fully underwritten A$750 million equity raising to fund its ambitious Towards 2030 growth strategy, aiming to expand rare earths production and downstream capabilities outside China.

Lynas Rare Earths reported FY25 results featuring record NdPr output and the first commercial heavy rare earths production outside China, alongside a $750 million equity raise to fund its ambitious Towards 2030 growth strategy.

BetMakers Technology Group reported a 10.6% revenue decline to $85.1 million for FY25 but achieved positive adjusted EBITDA and operating cash flow for the first time, signaling a strategic turnaround.

Tetratherix Limited reported a $9.4 million statutory loss for FY25 amid significant R&D and operational investments, successfully listing on the ASX and progressing multiple clinical and manufacturing initiatives.

Lumos Diagnostics reported an 11.4% revenue increase to US$12.4 million for FY2025, yet still posted a significant net loss amid auditor concerns over its future viability.

Micro-X Limited reported a $13.9 million loss for FY2025 as it pivots towards medical imaging, securing a landmark supply agreement with a major US healthcare provider for its Rover Plus mobile X-ray system.

GemLife Communities Group reported a 16% dip in net profit for H1 2025 but bolstered its balance sheet with a $750 million IPO and a strategic $220 million acquisition.